Currently Viewing:
Newsroom
Currently Reading
DPP-4 Inhibitors Subject of FDA Safety Warning
September 07, 2015 – AJMC Staff
Young at Heart? Most Americans Aren't, CDC Research Finds
September 03, 2015 – Mary K. Caffrey
"Happy Meal" Study Gives New Life to NYC Council Proposal
September 02, 2015 – Mary K. Caffrey
Dexcom G5 Mobile CGM System Approved by FDA
September 01, 2015 – AJMC Staff
New 340B Draft Guidance May Increase Bureaucracy
August 31, 2015 – Surabhi Dangi-Garimella, PhD
Synjardy Joins Ranks of Combo Therapies for Type 2 Diabetes
August 31, 2015 – Mary K. Caffrey
Short Bursts of Activity Can Offset Lack of Exercise in Kids, NIH Finds
August 28, 2015 – Mary K. Caffrey
Repatha, Amgen's PCSK9 Competitor, Gains FDA Approval
August 27, 2015 – Mary K. Caffrey
Obesity Increases Risk of Type 2 Diabetes Over Time, Study Finds
August 26, 2015 – Mary K. Caffrey

DPP-4 Inhibitors Subject of FDA Safety Warning

AJMC Staff
FDA has warned that the drug class dipeptidyl peptidase-4 (DPP-4) inhibitors may cause joint pain that can be severe and disabling. In a statement, the FDA said said it had issued a "warning and precaution" to all labels in this drug class.
FDA has warned that the drug class dipeptidyl peptidase-4 (DPP-4) inhibitors may cause joint pain that can be severe and disabling. In a statement, the FDA said said it had issued a “warning and precaution” to all labels in this drug class.

The agency stated that patients should not stop taking their DPP-4 inhibitor medications, but should report any joint pain to their physician if it is severe and persistent. Healthcare professionals should consider these medications as a possible cause of severe joint pain and discontinue if appropriate.

DPP-4 inhibitors are prescribed to lower blood sugar levels in adults with type 2 diabetes. This drug class is available as a standalone therapy or as a combination therapy. Approved medications in this class are sitagliptin (Januvia), sitagliptin and metformin (Janumet), sitagliptin and metformin extended release (Janet XR), saxagliptin (Onglyza), saxagliptin and metformin extended release (Kombigllyze XR), linagliptin (Tradjenta), linagliptin and empagliflozin (Glyxambi), linagliptin and metformin (Jentadueto), alogliptin (Nesina), alogliptin and metformin (Kazano), and alogliptin and pioglitazone (Oseni).

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up